i3 Acquires ChinaGate, Providing Customers With Greater Access to Chinese Market
i3, a global life sciences services company and subsidiary of Ingenix, has acquired ChinaGate, a contract research organization (CRO) that provides product-development regulatory services for pharmaceutical, medical device and biotechnology companies looking to enter and access the Chinese market.
ChinaGate has guided customers – based in China and abroad – through China’s regulatory system to bring medical and consumer health care products to the Chinese market. In addition, ChinaGate has helped its customers bring products manufactured in China to global markets.
ChinaGate has experience with the State Food and Drug Administration (SFDA), China’s regulatory authority charged with oversight and supervision of drugs and medical devices.
ChinaGate’s customers will gain access to development, data, and commercialization services through i3’s global reach. As a subsidiary of Ingenix, i3 offers systems, information, training, learning and development, and enabling technologies.
“ChinaGate will enhance i3’s ability to help our customers expand and sustain their business in the important Chinese market," said Glenn Bilawsky, CEO of i3.
“Combining i3’s and ChinaGate’s knowledge, experience, and expertise will enable us to offer clients more comprehensive services and continued results in one of the world’s fastest-growing pharma and medical-device markets,” said Joyce Chiu, CEO of ChinaGate.
The ChinaGate executive team, led by Chiu and Managing Director Janice Ma, will continue in their roles as ChinaGate integrates with i3’s Clinical Development Services group.
Market Opportunities in China
Global life science companies are increasingly turning to China to establish major research and development (R&D) capabilities and product development services. By 2020, China is targeting an investment of 2.5 percent of GDP into pharmaceutical R&D, putting China into a range comparable with that of the United States.
As disease patterns and prevalence in the Chinese population have begun to resemble those of the West, 75 percent of China’s total drug development pipeline is now in i3’s areas of therapeutic specialization, including oncology, central nervous system diseases, infectious disease, cardiovascular disease, and endocrine/metabolic conditions.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Regulatory Compliance With eCOAs
April 26th 2024In the fourth and final part of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA discusses how the regulatory stance on electronic clinical outcome assessments has changed over the years and what it could look like in the future.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
